The Technical Analyst
Select Language :

Tricida Inc [TCDA]

Exchange: NasdaqGS Sector: Healthcare Industry: Drug Manufacturers General Specialty & Generic

Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals

Tricida Inc is listed at the NASDAQ Exchange

-3.77% $7.40

Last updated: 28 Nov 2021 @ 16:52 pm


FUNDAMENTALS
MarketCap: 407.85 mill
EPS: -3.61
P/E: 0.000
Earnings Date: Feb 23, 2022
SharesOutstanding: 55.11 mill
Avg Daily Volume: 0.247 mill
RATING 2021-11-26
B+
Buy
RATING DETAILS
Rating CashFlow: Strong Buy
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Strong Buy
P/E: Sell
Price To Book: Strong Buy
QUARTER GROWTHS
2/203/204/201/212/213/21
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 0.000 | sector: PE 67.21
PE RATIO: COMPANY / INDUSTRY
0.00x
Company: PE 0.000 | industry: PE 18.73
DISCOUNTED CASH FLOW VALUE
$10.16
(37.29%) $2.76
Date: 2021-11-28

Insider Trading

Date Person Action Amount type
2021-11-18 Coufal Sandra I Sell 800 Common Stock
2021-11-17 Coufal Sandra I Sell 10 297 Common Stock
2021-11-15 Klaerner Gerrit Sell 126 000 Common Stock
2021-11-15 Parker Geoffrey M. Buy 166 667 Common Warrants
2021-11-15 Parker Geoffrey M. Buy 166 667 Common Stock
INSIDER POWER
88.56
Last 100 transactions
Buy: 5 065 735 | Sell: 382 308

Forecast: 14:40 - $7.49

Live Trading Signals (every 1 min)

Forecast 1: 13:10 - $7.39
Forecast 2: 14:00 - $7.49
Forecast 3: 14:40 - $7.49
SCORE
-4.20
Sell
Score Algorithm Version: 0.9M
Last version updated: Thurs 28th Oct 2021
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $7.40 (-3.77% )
Volume 0.0691 mill
Avg. Vol. 0.247 mill
% of Avg. Vol 27.97 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Tricida Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Tricida Inc

RSI

Intraday RSI14 chart for Tricida Inc
The Live Chart for Tricida Inc
Profile picture for
            Tricida Inc

TCDA

Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). The company has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Last 10 Buy Signals
Date Signal @
XRPUSDNov 28 - 11:510.918
XRPUSDNov 28 - 11:440.914
BTCUSDNov 28 - 11:2954 102
DOGEUSDNov 28 - 11:29$0.198
XRPUSDNov 28 - 11:230.920
XRPUSDNov 28 - 11:100.924
XRPUSDNov 28 - 10:590.926
XRPUSDNov 28 - 10:550.928
BTCUSDNov 28 - 10:5354 420
DOGEUSDNov 28 - 10:46$0.201

Stock Peers

Company Price Change
TCDA7.40-3.77%
ASLN1.5302.68%
CDMOP25.060.04%
CKPT3.14-3.09%
CRBP0.884-3.06%
CTIC2.485.98%
MNOV3.22-9.80%
OBSV2.240.00%
ORPH3.30-2.94%
SMTI28.65-1.21%
VTVT1.340-2.19%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.